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The allostatic load (AL) index constitutes a useful tool to objectively assess the biological
aspects of chronic stress in clinical practice. AL index has been positively correlated with
cumulative chronic stress (physical and psychosocial stressors) and with a high risk to
develop pathological conditions (e.g., metabolic syndrome, cardiovascular pathology,
inflammatory disorders) and the so-called stress-related psychiatric disorders, including
anxiety and depressive disorders. Chronic stress has negative effects on brain
neuroplasticity, especially on hippocampal neurogenesis and these effects may be
reversed by antidepressant treatments. Several evidences indicate that non-
pharmacological interventions based on physical activity and yoga practice may add
synergizing benefits to classical treatments (antidepressant and benzodiazepines) for
depression and anxiety, reducing the negative effects of chronic stress. The aim of this
review is to provide a general overview of current knowledge on AL and chronic stress in
relation to depression and anxiety, physical activity and yoga practice.
Keywords: chronic stress, neuroplasticity, neurogenesis, hippocampus, cortisol, noradrenaline,
antidepressants, benzodiazepinesINTRODUCTION
The concept of allostatic load (AL) index, has been introduced by Bruce McEwen and Stellar in 1993
to objectively assess the biological consequences of chronic stress in the body and the brain (1).
Psychosocial factors related to poverty and health risk behaviors across the lifespan have been
associated with higher AL index (2, 3). AL index has been positively correlated with cumulative
chronic stress (physical and psychosocial stressors) and with a high risk to acquire medical
conditions (e.g., metabolic syndrome, cardiovascular pathology, inflammatory disorders) (4–8).
Moreover, chronic stress and AL overload may contribute to the expression of the so-called stress-
related psychiatric disorders, especially represented by anxiety and depressive disorders (5, 9–12).
Furthermore, chronic stress through hypercortisolemia can induce negative effects on braing June 2020 | Volume 11 | Article 5011
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and these effects may be reversed by antidepressant treatments
(17, 18).
Evidences based on experimental data and studies in human
patients indicate that physical activity and yoga practice might
bring about benefits not only in adult hippocampal neurogenesis
and neuroplasticity (19), but also on stress related psychiatric
symptoms (anxiety and depression) (20, 21) as well as on AL
index (22, 23). Non-pharmacological interventions and classical
treatments (psychotherapeutic and pharmacological approaches)
may have synergistic effects on brain function and clinical
symptoms which helps building the idea of managing
depression and anxiety disorders using combined treatments
(19, 21). The implementation of these strategies as add-on
therapy may optimize the pharmacological treatment reducing
the risk of adverse side effects. Therefore, the aims of this review
are to provide an overview of the biology aspects of AL and
chronic stress in reference to depression and anxiety, and to
describe the current knowledge on the non-pharmacological
interventions based on physical activity and yoga practice upon
AL, depression and anxiety.THE ALLOSTASIS CONCEPT AND THE
ALLOSTATIC LOAD INDEX
The term allostasis refers the ability to achieve stability through
changes in response to stress and/or stressful events (4). The
most important systems involved in the stress response are the
hypothalamic-pituitary-adrenal (HPA) axis, the autonomic
nervous system and the inflammatory system, with their
respective biochemical mediators, the glucocorticoids, theFrontiers in Psychiatry | www.frontiersin.org 2catecholamines (adrenaline and noradrenaline) and the
cytokines. These compounds produce physiologic effects that
are adaptive in the short term, however they can be harmful in
the long term (chronic stress) (4, 5, 10, 13).
The AL index was proposed with the aim of measuring the
cumulative influence of stress on health through a series of
clinical and biochemical indicators of the main systems
potentially affected (4, 6). Essentially, the AL index constitutes
a marker of cumulative biological risk of chronic stress which
describes the additive effects of multiple clinical situations that
may accelerate the vulnerability to diseases reducing resilience (9,
10, 24–26). The AL index was found to be a good predictor of
mortality and physical functioning (27). The clinimetric
definition of AL overload, firstly introduced by Feinstein in
1987 to define clinical measurements related to chronic stress,
was recently described by Fava and McEwen et al. in 2019 (27).
These authors proposed two main criteria: the presence of a
current source of distress added to previous symptoms or
functioning impairment (27).
AL index includes different biological markers divided in two
main groups; 1-Primary mediators: represented by stress
hormones (adrenaline, noradrenaline, and cortisol) in
combination with inflammatory cytokines (e.g., interleukin-6,
tumor necrosis factor), 2- Secondary mediators: represented by
biomarkers of metabolic, cardiovascular, and immune systems
that compensate primary mediators alterations [e.g., insulin,
glucose, total cholesterol, high density lipoprotein cholesterol,
triglycerides, visceral fat depositing, systolic and diastolic blood
pressure, fibrinogen, c-reactive protein; (2, 8, 28)]. Different
authors have applied the AL index in population-based studies
and/or in clinical trials and studied the association with
depression and anxiety disorders (8, 11, 28–32). Table 1
summarizes the AL index and the cut off points analyzed in aTABLE 1 | Allostatic load parameters and cut-off points.
Affected systems Allostatic Load Parameters Cut-off points (for AL index) (32)
Primary mediators
HPA-Cortisol Cortisol >32nM Salivary
DHEA (dehydro-epi-androsterone) <80 ng/ml in men
<35 ng/ml in women (plasma)
Autonomic System Noradrenaline >100pg/ml (plasma)
MHPG (methoxy-hydroxy-phenylglycol) >2,750nM (salivary)
Secondary mediators
Cardiovascular Systolic blood pressure >140 mmHg
Diastolic blood pressure >90 mmHg
Metabolism: Lipids and adipose tissue deposition Body Mass Index >25
Waist-hip ratio >1 in men
>0.8 in women
Total cholesterol >200 mg/dl (plasma)
LDL (low density lipoprotein) >120 mg/dl (plasma)
HDL (high density lipoprotein) <37 mg/dl (plasma)
Total cholesterol/HDL ratio >3.5 mg/dl (plasma)
Metabolism: Glucids, proteins and renal function Glycated hemoglobin >6mg/dl (plasma)
Creatinine >1.2mg/dl (plasma)
Albumin <3.5 g/dl (plasma)
Immune System C-reactive protein >7.1mg % (plasma)
Fibrinogen >400mg/dl (plasma)June 2020 | Volume 11 | Article 501
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anxiety disorder (12, 32).DEPRESSION, ANXIETY, AND AL
The relationship between chronic stress, depression and anxiety
has been extensively described (5, 9, 10, 13). Experimental
models showed that stress hormones (glucocorticoids) acting
on the brain, may modify emotional arousal, predisposing to
depression- and anxiety-like behavior (33). Furthermore,
chronic stress models in rodents can cause changes in brain
neuroplasticity and changes in behavior consistent with
depressive- and anxiety-like symptoms (5, 9, 10, 13, 33–36).
In humans, the administration of exogenous glucocorticoids
may produce psychiatric adverse effects, such as steroid
psychoses and depression. These symptoms may be blocked by
the glucocorticoid antagonist mifepristone (37, 38). In patients
with major depressive disorder, cortisol levels are elevated, the
diurnal rhythm is distorted and the HPA axis is resistant to
suppression by dexamethasone (9, 33, 37, 38). Moreover, higher
AL index has been associated with higher levels of depressive
symptoms in many studies (8, 11) (28–30, 39). Compared with
patients with personality disorders, emergency psychiatric
patients primarily diagnosed with bipolar, depressive, or
anxiety disorders showed altered AL parameters including
cortisol, interleukin-6, systolic blood pressure, and heart rate
(11). Also, higher AL index were significantly associated with
depressive symptoms (29) showing variations according to sex,
gender, race, and sociocultural factors (30, 31).
Cardiovascular parameters of AL index were frequently altered
in patients with depression (11, 28, 29). Longitudinal cohort studies
showed increase risk of cardiovascular morbidity and mortality
among patients with comorbid depression (40). In a recent study,
Gillespie et al. analyzed the role of AL and depression in relation to
coronary heart disease. Greater depressive symptomatology was
associated with higher metabolic, cardiovascular, and immune AL
parameters, however coronary heart disease was associated to
depression, only in male population (28). Obesity, metabolic
abnormalities and higher expression of inflammatory markers
were also frequently observed in patients with depression (23, 30,
41). Compared with age- and gender-matched control groups,
individuals with major depression had higher metabolic syndrome
prevalence, hyperglycaemia, and hypertriglyceridemia (41).
Regarding anxiety, high levels of cortisol and CRH
(corticotrophin releasing hormone), have been associated to
fear states and anxiety-like behavior in experimental models
(13, 33). Disturbances in the HPA with hypercortisolemia were
reported among patients with anxiety disorders, in patients with
panic disorder (42) and in patients with general anxiety disorder
(32, 43). In addition, sympathetic hyperactivity with high levels
of methoxyhidroxiphenilglicol (MHPG) (the main metabolite of
noradrenaline) was also reported in patients with anxiety
disorder (32, 44, 45).
Sex and age related differences in psychiatric symptoms and
AL parameters were also described in the literature (28–30, 32,Frontiers in Psychiatry | www.frontiersin.org 346). Firstly, a higher prevalence and severity of depression and
anxiety disorders has been reported in women compared to men
(29, 32, 47). Biological differences have been proposed to explain
such differences since experimental studies in rodents suggest sex
differences in the neural remodeling pattern after stress (10, 48).
However, psychosocial influences cannot be excluded as women
are also more exposed to psychosocial stress and trauma (30, 49,
50). Women in fertile age are less prone to cardiovascular disease
and mortality than men (28, 31, 51, 52). In a previous study of
our group in patients with anxiety disorders, women showed
higher anxiety levels than men, with a better profile in many
individual AL variables, particularly cardiovascular (systolic
blood pressure), obesity (body mass index), and lipids with
higher HDL (high density lipoprotein cholesterol) levels (32).
On the opposite, AL inflammatory parameters tended to be
higher in women (30, 46, 52). Regarding age factors, elderly
patients were more vulnerable to stress-related disorders and
expressed higher levels of cumulative AL (2, 6, 7, 32).CHRONIC STRESS AND HIPPOCAMPAL
NEUROPLASTICITY: THE ROLE OF
ANTIDEPRESSANT TREATMENTS
The hippocampus has been in the focus of stress research
especially after the finding that glucocorticoids receptors are
abundantly expressed in hippocampal cells (53). A large body of
evidence in rodents demonstrated that chronic stress, via
elevated levels of glucocorticoids, can affect both hippocampal
structure and function (16, 33, 54) and can also induce
depressive-like behavior (18). Adult hippocampal neurogenesis
(the brain capacity to develop new neurons during adult life)
(55), decrease with age and is especially affected by chronic stress
(15, 56, 57).
Hippocampal structure and function might be altered in
patients with depression. Reductions in hippocampal volume
based on magnetic resonance imaging studies have been
consistently documented in patients with major depression
(58, 59). For example, patients suffering from recurrent
depressive episodes showed lower hippocampal volume (60,
61). Similarly, in Cushing's disease, the duration of the illness
predicts a progressive reduction in the hippocampus volume,
which was determined by structural magnetic resonance imaging
(62). Besides, the atrophy of the hippocampus has also been
reported among patients with anxiety-related disorders and post-
traumatic stress disorder (63). Moreover, depression is a
common comorbidity in patients with resistant temporal lobe
epilepsy and hippocampal sclerosis (14, 64, 65).
In humans, adult hippocampal neurogenesis occurs in the
hippocampal dentate gyrus, and newborn neurons can be
produced from neural stem cells which can be classified based
on their distinctive morphology as radial glia-like (66) and non-
radial glial cells (67). Chronic physical stressors, chronic
psychosocial stressors, and chronic unpredictable stressors, can
inhibit one or more phases of the adult hippocampalJune 2020 | Volume 11 | Article 501
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regulate adult hippocampal neurogenesis might be affected by
chronic stress: The enhance of glutamate release via NMDA (N-
methyl-D-aspartate receptor), the reduction of GABA (Gamma
aminobutyric acid) levels, the reduction of 5HT (serotonin)
levels and the down regulation of 5HT1A (serotonin receptor
1A; stimulation of 5HT1A is pro-neurogenic), and the alterations
in noradrenaline, dopamine, and endocannabinoids were
described (18, 57, 68). Stress can also reduce the expression of
neurotrophic factors involved in adult hippocampal
neurogenesis regulation (e.g., brain-derived neurotrophic
factor, insulin-like growth factor-1, neuregulin-1; 69, 70).
Neurotrophic factors have been shown to increase adult
hippocampal neurogenesis and also modulate antidepressant-
related effects and behavior in experimental models (18, 71).
Adult hippocampal neurogenesis is involved in mediating the
response to antidepressant drugs (18, 72). The suppression of
adult hippocampal neurogenesis achieved by chronic stress can
be prevented by administering antidepressants (72, 73) which
reverse the inhibitory effect of stress after 3–4 weeks of treatment
(time course of maturation for newly generated neurons) (17,
72–75). Antidepressants require of adult hippocampal
neurogenesis mechanisms to be effective (57, 76) and involve
the activation of glucocorticoid receptors in the hippocampus
(77). The stimulation of adult hippocampal neurogenesis has
been considered a promising property for identifying new
ant idepressant targets . At the moment almost a l l
antidepressant treatments including pharmacotherapy and
behavioral interventions, proved to stimulate adult
hippocampal neurogenesis (15, 57, 78).CHRONIC STRESS AND ANXIETY: ROLE
OF ANXIOLYTICS TREATMENTS
During stress response sympathetic system is simultaneously
activated with HPA system, and both noradrenaline and cortisol
are released, amplifying the emotional response (4, 5, 10, 13).
Anxiety has been proposed as an undifferentiated form of fear or
rage, discharged by noradrenaline and cortisol (79). Anxiolytic
drugs acting through a positive allosteric modulation of GABA-
A receptor (benzodiazepines), reduce the sympathetic discharge
leading to lower plasma levels of catecholamines (80–82) and
lower salivary levels of MHPG (44, 45, 83, 84). Benzodiazepines,
particularly those of high-potency such as alprazolam, have
demonstrated anti-hypertensive pleiotropic properties in
patients with high blood pressure without affecting the heart
rate (81, 85). In our previous work (32), low doses of alprazolam
during 12 weeks reduced anxiety levels and the total AL index.
We observed a significant reduction on salivary levels of MHPG
and on systolic blood pressure (12, 32). As well pharmacotherapy
with benzodiazepines in association to psychotherapy
demonstrated to be effective in reducing anxiety and AL
parameters (86), the risk of inducing pharmacological
dependence and/or cognitive adverse events should be
considered requiring continuous monitoring (87–89).Frontiers in Psychiatry | www.frontiersin.org 4NON-PHARMACOLOGICAL STRATEGIES,
PHYSICAL ACTIVITY, AND YOGA
PRACTICE
Physical Activity
Many studies based on experimental research in rodents
demonstrated that physical activity interventions may promote
hippocampal neuroplasticity, counteracting the negative effects
of chronic stress on the brain (15, 19, 90–95). Models of aerobic
exercise potently stimulate adult hippocampal neurogenesis,
inducing higher rates of proliferation and/or survival of
newborn cells (15, 90). Also, higher synaptic plasticity and
higher levels of BDNF (Brain Derived Neurotrophic Factor),
were observed in hippocampus, after voluntary and involuntary
exercise (91, 92). Additionally, the use of combined treatments
(e.g., aerobic exercise and antidepressant treatments), has
stronger effect on depressive behavior and on BDNF up-
regulating, than antidepressant treatment or aerobic exercise
acting individually (93–95).
In humans, neuroimaging studies using MRI (Magnetic
Resonance Image) demonstrated that physical activity
increased the hippocampal volume and positively correlated
with better performances on hippocampus dependent tasks
(episodic memory) (96). Physical activity can enhance some
indirect signs of neuroplasticity (e.g., increased cerebral blood
flow or BDNF plasma concentration) (96). Plasma levels of
BDNF have been proposed as a potential biomarker of
depression treatment. Serum BDNF is decreased in depressed
patients and can be normalized with antidepressant treatment
together with moderate to intense physical activity (97, 98).
Physical activity has been considered a non-stigmatizing
intervention with few side effects and has been associated with
the relief of depression and anxiety symptoms in different studies
(20, 21, 99, 100). Different types of physical activity (aerobic,
stretching, leisure-physical activities, dance, yoga asanas), have
been associated with lower depression and anxiety prevalence in
population-based studies (23, 100–102), with a better outcome in
patients with depressive disorders (103–106) and with lower
scores of self-reported stress, anxiety, and depression scales in
healthy subjects (107–109). Physical activity may prevent the
development of depression during the follow up according
prospective studies (23, 100, 102), can reduce de the risk of
anxiety (110) and may enhance the cognitive performance (97)
contributing with antidepressant drugs and/or cognitive-
behavioral therapy (111). In a meta-analysis of relevant
randomized controlled clinical trials, aerobic exercise showed
moderate to large effects for patients with major depression and
favoured over classical psychological treatments or
antidepressants drugs (20). Physical activity may act as an
adjunctive treatment to traditional medication and
psychotherapy, resulting in a more effective approach toward
relief of psychiatric symptoms and AL (19, 20, 99, 105).
Table 2 resumes the main recent studies that have analyzed
physiological AL parameters and the effects of physical activity
(and/or yoga asanas) on depression and anxiety outcome. All
resumed studies, population-based studies and clinical trials,June 2020 | Volume 11 | Article 501
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outcome in healthy subjects and in patients with depression.
Although the total AL index was not measured, some of these
studies analyzed certain AL parameters outcome. Obesity factors
were positively associated with depression and negatively with
physical activity (23). A lower fitness level in cardiopulmonary
exercises was observed in patients with depression (104). Minor
resting pulse was associated with physical activity and lower riskFrontiers in Psychiatry | www.frontiersin.org 5to develop depression in healthy subjects (100). Also, lower heart
rate and diastolic blood pressure and higher HDL cholesterol,
were observed among inpatients with major depressive disorder
who underwent to a physical activity-training program (105).
Regarding the effects of physical activity on AL parameters sex
differences were also reported (106, 112). Women showed higher
levels of c-reactive protein, which positively correlated with
measures of adiposity and inversely associated with fitness,TABLE 2 | Description of the studies that have been analyzed the physiological AL parameters and the effects of physical activity and yoga asanas on anxiety and
depression outcome.
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inflammation in women (106). Although these preliminary
findings are promising, larger and adequately powered
randomised controlled trials are needed to better evaluate the
combined effect of physical activity and classical treatments on
allostatic load and on depression and anxiety.
Yoga Practice
In the last years, yoga has become popular in western cultures
and constitutes an interesting tool for stress management.
Although yoga originated in India, different yoga styles are
practiced in western societies at present. Most of the different
styles contain physical postures (termed asana in Sanskrit), as
well as breath control exercises (pranayama) and meditation
(dyana) (113). A meta-analysis of randomised controlled trials
performed on healthy subjects and on patients with medical
conditions (e.g cardiopathy, hypertension, metabolic syndrome,
obesity, breast cancer), showed that yoga practice may reduce
physiological measures of stress, including cortisol, autonomic
measures (systolic blood pressure, heart rate), cytokines, and
lipid levels (21). Also, yoga practice showed positive effects onFrontiers in Psychiatry | www.frontiersin.org 6depression and on anxiety symptoms in pregnant women (114),
improved the mood states in psychiatric inpatients (115) and had
beneficial effects on depression outcome in patients with major
depressive disorder (116–118).
Regarding AL parameters, attenuated and decreased levels of
salivary cortisol after yoga practice were reported in clinical trials
on healthy patients(107, 108). These results correlated with lower
perceived stress and negative affect (108) and with better
cognitive functions, lower self-reported stress, and minor
anxiety levels (107) (Table 2). Clinical evidences showed that
yoga asanas can modulate the autonomic nervous system
inducing higher parasympathetic activity, lower blood pressure,
lower heart rate, higher relaxation and approach behaviors (21,
119). In a recent study using magnetic resonance spectroscopy
yoga practice has been associated to higher GABA levels in
patients with major depressive disorder (118).
A combination of body awareness-yoga asanas and
mindfulness meditation has been developed in a complete
program for stress reduction (21) and has been proposed to
clinicians as a safe and effective technique to reduce stress and
anxiety in diverse patient populations (21, 120, 121) reducingTABLE 2 | Continued
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African dance and hatha
yoga significantly
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stress and negative affect,
compared to the biology
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well-being (107, 122–124). Yoga practice effectively decreases
depressive and anxious symptomatology, although the
neurobiological mechanisms involved are not totally elucidated
(21). Regarding brain effects, neuroimaging studies
demonstrated that hippocampus is activated during yoga
practice (113, 125, 126). Moreover, a significantly greater
hippocampal volume has been found in experienced yoga
practitioners (113, 126, 127) and higher volumetric measures
in different brain areas were positively correlated with the years
of yoga practice (113).CONCLUSIONS
Non-pharmacological interventions such as physical activity and
yoga practice may exert synergizing effects to antidepressant and
anxiolytic treatments. The classical treatment of patients with
anxiety disorders and depression is psychotherapy, but
pharmacotherapy is recommended when psychiatric symptoms
are severe enough to induce a significant functional impairment
(86). Antidepressants and/or benzodiazepines are indicated
(National for Health and Clinical Excellence, UK guidelines) to
treat these disorders (86). However, pharmacological treatments
may be associated with adverse side effects. Physical activity and
yoga practice have been shown to elicit improvements in anxiety
and depression symptoms conducting to a better social, physical,Frontiers in Psychiatry | www.frontiersin.org 7and affective well-being optimizing the pharmacological
treatment duration and the risk of pharmacological adverse
side effects. However, larger and adequately powered
randomized controlled trials are needed to evaluate the
combined effect of physical activity on allostatic load and on
depression and anxiety. Also, is important to emphasize that
future studies are needed to reveal the biological mechanisms
involved in the therapeutic actions of physical activity and yoga,
in particular on depression and anxiety. Furthermore, stratified
interventions according to sex and age should be considered in
the future to track the therapies toward an individualized
schedule in agreement with the current medical practice.AUTHOR CONTRIBUTIONS
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88. Billioti S, Gage D, Bégaud B, Bazin F. Benzodiazepine use and risk of
dementia : prospective population based study. BMJ (2012) 345:e6231–e
6231. doi: 10.1136/bmj.e6231
89. Soria CA, Remedi C, D'Alessio L, Roldán EJA. Semantic and Phonemic
Verbal Fluency Performance in Patients with General Anxiety Disorders and
Allostatic Load under Alprazolam Treatment. Open J Psychiatry (2019) 9
(2):138–52. doi: 10.4236/ojpsych.2019.92011
90. Brown J, Cooper-Kuhn CM, Kempermann G, Van Praag H, Winkler J, Gage
FH, et al. Enriched environment and physical activity stimulate hippocampal
but not olfactory bulb neurogenesis. Eur J Neurosci (2003) 17(10):2042–6.
doi: 10.1046/j.1460-9568.2003.02647.x
91. Vaynman S, Ying Z, Gomez-Pinilla F. Hippocampal BDNF mediates the
efficacy of exercise on synaptic plasticity and cognition. Eur J Neurosci
(2004) 20(10):2580–90. doi: 10.1111/j.1460-9568.2004.03720.x
92. Uysal N, Kiray M, Sisman AR, Camsari UM, Gencoglu C, Baykara B, et al.
Effects of voluntary and involuntary exercise on cognitive functions, and
VEGF and BDNF levels in adolescent rats. Biotech Histochem (2015) 90
(1):55–68. doi: 10.3109/10520295.2014.946968
93. Russo E, Citraro R, Scicchitano F, Urzino A, Marra R, Rispoli V, et al.
Vigabatrin has antiepileptogenic and antidepressant effects in an animal
model of epilepsy and depression comorbidity. Behav Brain Res (2011) 225,
1:373–6. doi: 10.1016/j.bbr.2011.07.030
94. Baj G, D'Alessandro V, Musazzi L, Mallei A, Sartori CR, Sciancalepore M,
et al. Physical exercise and antidepressants enhance BDNF targeting in
hippocampal CA3 dendrites: Further evidence of a spatial code for BDNF
splice variants. Neuropsychopharmacology (2012) 37(7):1600–11. doi:
10.1038/npp.2012.5
95. Duman RS, Aghajanian GK. Synaptic dysfunction in depression: Potential
therapeutic targets. Sci (80-. ). (2012) 338(6103):68–72. doi: 10.1126/
science.1222939
96. Erickson KI, Voss MW, Prakash RS, Basak C, Szabo A, Chaddock L, et al.
Exercise training increases size of hippocampus and improves memory. Proc
Natl Acad Sci U S A (2011) 108(7):3017–22. doi: 10.1073/pnas.1015950108
97. Toups MSP, Greer TL, Kurian BT, Grannemann BD, Carmody TJ,
Huebinger R, et al. Effects of serum Brain Derived Neurotrophic Factor
on exercise augmentation treatment of depression. J Psychiatr Res (2011) 45
(10):1301–6. doi: 10.1016/j.jpsychires.2011.05.002
98. de M Coelho FG, Gobbi S, Andreatto CAA, Corazza DI, Pedroso RV,
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